Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from melanoma

FED:State funeral for research pioneer as cancer fight ends

"Remarkable" melanoma pathologist and former Australian of the Year Richard Scolyer, who died from brain cancer aged 59, will have a state funeral.

AAP

FED:Scientist Richard Scolyer dies after cancer battle

World-renowned melanoma pathologist and former Australian of the Year Richard Scolyer has died from brain cancer aged 59.

AAP

Richard Scolyer, acclaimed melanoma researcher who tried experimental treatment on his own brain cancer – obituary

Pathologist and athlete who was Australian of the year in 2024 underwent a bold experimental treatment after devastating brain cancer diagnosis

The Guardian - AU

From analysis to the latest developments in health,
read the most diverse news in one place.

Richard Scolyer, cancer researcher and former Australian of the year, dies aged 59

Scolyer, who did pioneering work on immunotherapy, was diagnosed with inoperable brain cancer in 2023

The Guardian - AU

Lauded cancer doctor dies, leaving scientific legacy

Professor Richard Scolyer was a joint Australian of the Year for research into melanoma treatment before developing techniques to fight his own brain cancer.

AAP

FED:Renowned doctor Scolyer dies after public cancer battle

Renowned melanoma pathologist and father of three Richard Scolyer has died at the age of 59.

AAP

Pioneering researcher remembered as cancer fight ends

A renowned pathologist and former Australian of the Year has been remembered as a selfless fighter who strived to improve the lives of others.

AAP

Read news from The Economist, FT, and more,
with one subscription

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Therapeutic Goods Administration (TGA) of Australia granted approval with conditions of…

AAP

Melanoma is the deadliest form of skin cancer. A new vaccine-drug combo could slash recurring cases

An estimated 112,000 new melanoma cases and 8,500 deaths are expected this year

The Independent UK

Dermatologists rubbish ‘dangerous’ claims that tanned skin protects against sunburn

Melanoma is the most aggressive form of skin cancer causing about 2,600 deaths a year in the UK – many are linked to sunbed use

The Independent UK

Q&A: Justin Thomas on a Life-Changing Moment, Sun Protection and Shinnecock Hills

The two-time major champion has his own suncare brand, which all started with dermatologist visit back in 2019.

Sports Illustrated

Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances

Aura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen’s se

MarketBeat

IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit

IDEAYA Biosciences (NASDAQ:IDYA) executives highlighted recent clinical progress across the company’s oncology pipeline during a fireside chat at TD Cowen’s seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several ear

MarketBeat

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing

IDEAYA Biosciences (NASDAQ:IDYA) Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline. Speaking at a Stifel-hosted event, H

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Newcastle Herald

'It was all through my body': tradie's blunt message for outdoor workers

A big work and safety issue that needs more understanding.

The Conversation

First video of immune cells eating live skin cancer in real time

For the past 15 years or so, a class of drugs called immune checkpoint inhibitors have been used to treat melanoma – the most dangerous kind of skin cancer.

International Business Times UK

Deadliest Skin Cancer Cases Hit Record High in the UK as Experts Blame Sun Exposure and Sunbed Use

UK melanoma cases hit a record high with 20,000+ yearly diagnoses as experts warn excessive UV exposure and sunbed use raise risks.

The Guardian - UK

Melanoma skin cancer cases in UK hit record level, analysis finds

Cancer Research UK figures show number diagnosed with most serious form of skin cancer has risen above 20,000 for first time

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Melanoma skin cancer cases hit record high in the UK as heatwave warning issued

Cancer Research UK urged people to enjoy the sun safely by covering up and using sunscreen

Evening Standard

Sun safety warning issued for bank holiday as skin cancer cases hit record high

Cancer Research UK data for the year 2022 shows there were 20,980 new cases of melanoma, the highest number it has ever seen.

MarketBeat

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data

Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial development focus while also discussing ongoing work in non-muscle invasive bladde

Barchart

Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

MarketBeat

IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting several pipeline programs during a presentation at the Bank of America Global Healthcare Conf

The Independent UK

RFK Jr withdraws proposal banning teens from tanning beds as skin experts warn of cancer risks

Using tanning beds can triple a person’s risk of melanoma, according to experts

The Independent UK

Skin cancer warning as one in nine Britons admit to deliberately burning themselves to tan

Research shows that having five or more sunburns doubles your risk of getting melanoma skin cancer

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

the University of Sydney

Regeneron Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.